Member Info for PJT12

beinthelead, it's not me that you need to be addressing. I've merely pointed out the obvious. It is precisely because too many DON'T challenge that so-called "Troll" sensibly that I wrote. Counter him through factual logic and certainly with less emotion / vitriol than we see on this board all too regularly. Professional responses will win over prospective investors rather than bickering.

O&A, the administrator will kick out anybody who is anything other than a serious investor.

No spaces.

t . me/joinchat/

The missing bit:
**************

Yuyus, here it is:

https://**************S2IyuK-jcWdMDhYI

........and me :-)

Yuyus, I assume from your enthusiasm that you are in the Angle Telegram group? Some decent and knowledgeable types in there.

Pigster, appreciate the well balanced response. If only all discussions on these boards were as well intended.

See myself as often contrarian but definitely not Wyndrum although I do think he's another who - although more intelligently posting than MFM - will only irritate those in it for a fast buck. The future's rightly bright for people with a properly considered LT view here.......

Whilst MFM is clearly a windup merchant, all he is doing is stating the obvious. That is clearly not going to go down well with some but I suspect the more serious and mature LTH here will be reading his posts with a wry smile and any resulting water will be flowing off them like that off a duck's back. I sincerely hope for the sake of the decent LTH holders on here such as Timster, Zoom, Monkshead and Pigster that it comes good on the sales front. However, I will again ask the question that I asked two months ago when I was informed that my ignorance lends itself to checking out the "sales CV" of one particular individual as that speaks volumes about him. Clearly not in the present world. That was before validation and in response to me asking if we need to be concerned about the lack of a decent sales team? I wonder what the response would be today from the poster who replied, "What's a sales team? Do you expect them to go around knocking on doors?" My question remains: What the hell has David Wilson been doing for the past six months? There is nothing more I would like than to see him prove me wrong but that CV continues to count for little on the current sales front. And, secondly, at what point can we expect 'home use' clearance? They are to two areas where I would be targeting for a rapid (further) SP improvement. Like I say, fingers crossed for the decent guys on here. For the others easily rattled by him, MFM has always been a pain - albeit quite an entertaining one for those of us on the sidelines - but he is easily ignored by those who genuinely believe in the company's longer term prospects.

Yes, the inevitable impending placing.

1. Bearing in mind Shield's increased focus on North America and the greater valuations for Life Sciences on that side of the Atlantic, do you see the company applying for a Nasdaq listing in future?
In common with most biotechs, a NASDAQ listing could be a logical step in due course and cannot be discounted.

2. The companies producing the IV solutions are obviously not going to sit back and let us eat into their market. To what extent do you think they will see us as a threat rather than just competition?

The IV companies may see us as both competition and a threat and will undoubtedly seek to denigrate Accrufer, but we should not be unduly concerned about this as IV therapy has very clear disadvantages.

Would certainly provide a hike in the SP as I think it'll arrive in the face of the 'unexpected' rather than 'expectation' at this point. That said, I would certainly not bet against something decent in the next couple of weeks.

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, confirms that its Annual General Meeting (AGM) will be held as a closed meeting at 2:00 pm on Wednesday 30 June 2021. Shareholders who wish to attend the AGM online should register for the event in advance via the following link: https://www.investormeetcompany.com/angle-plc/register-investor.

The Company will also be providing a business update for Shareholders after the formalities of the AGM are concluded. Shareholders may submit questions to the Board in advance of the AGM and business update by email to investor@angleplc.com before 5.00 pm on TUESDAY 29 JUNE 2021. The Board will not be able to answer all individual questions but will group the questions into themes and will endeavour to answer these during the update or as part of concluding matters.

Roundhowe, don't blame the wider public for reading "corruption" between the lines where perhaps there is none because based upon any ties to the current government's record it is very easy to do. The latest from their leader? BJ now tries to tell us that he took decisive action in sacking Han****. Sorry but even for me as a Tory this govt and many of its "associates" stinks! Why would we ever trust any of them judged on their actions?

He went to Eton College.....surprisingly. The smell just seems to get ever worse.

Yes, champagnecharlie, so a positive PSA (or Grail) test (the basic screening) that has already determined the "elevated PSA" will need to be followed by running a blood sample through Parsortix (for deeper analysis) to enable closer examination of captured cells, as with the other cancers ANGLE is targeting. "Ahead of prostate tissue biopsy" merely means that Parsortix will replace the need to undertake tissue removal under the knife. I suspect we will just need to agree to disagree but either way Parsortix is hugely preferable to the current options and will revolutionise the process.

Fairly sure I've got this right but open to others more knowledgeable correcting me?

Hang on a mo' tho'. Isn't the only difference they are talking about in thursday's RNS the type of cancer cell / cluster they will be capturing? Surely, Parsortix would only be used to investigate further off the back of the likes of a positive Grail test, in this case though for prostate cancer?

champagnecharlie, that'll teach me not to keep up properly! My over-enthusiasm in trying to highlight how Parsortix is superior / different to Grail obviously blinded me to a massive plus-point that I should've picked up on. I too am obviously very excited by that now you've made me aware of it and appreciate the correction.